Overall verdict
Neutral
6.3/10
1-year performance
+35.31%
Score breakdown
Up 35.3% over 1 year, 79% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 2.3/10.
32 analysts, target +0.1% vs the price.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older ;
ALYFTREK for the treatment for people with CF 6 years of age and older ; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older ; ORKAMBI for CF patients 1 year or older ; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT ; JOURNAVX for the treatment of acute pain in adults ;
VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial ; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial ; VX-264 for treating Type 1 Diabetes ; VX-670 for the treatment of myotonic dystrophy type 1 ; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Reshma Kewalramani
Founded
1989
Employees
6 400
Revenue / employee
1.9M USD
Next earnings
November 2, 2026 (Q3 2026)
Institutional holders
- Capital World Investors10.40%
- BlackRock, Inc.9.60%
- Capital Research Global Investors7.76%
- VANGUARD CAPITAL MANAGEMENT LLC6.60%
- STATE STREET CORP4.73%
- Invesco Ltd.3.20%
- JPMORGAN CHASE & CO2.60%
- GEODE CAPITAL MANAGEMENT, LLC2.40%
- VANGUARD PORTFOLIO MANAGEMENT LLC1.94%
- Other institutions46.77%
- Rest of the register4.00%
1752 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
560.25 USD
52-week low
377.02 USD
1-year performance
35.31%
Rising
Year-to-date performance
13.65%
Rising
Drawdown
-6.98%
Mild pullback
Position in the 52-week range
79% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.9 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Vertex | 180 613 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.9 times as much as the world ETF.
- Worst fall:-44 % between July 2015 and October 2016. 10,000 € placed at the top fell to 5 611 €. The world ETF, at worst: -34 %. Back to its high in 9 months.
Vertex earned 2 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Vertex: 180 613 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 396.07 USD - 448.19 USD (3 methods agree)
The price implies growth of 12.12% per year; the company grows at 8.28%.
Gross margin 86.1%, net margin 34.7%, ROIC 21.5%, ROE 23.5%.
Net margin
34.69%
Exceptional
Sector -15.62%|S&P 12.97%
Gross margin
86.12%
Fair
Return on equity (ROE)
23.54%
High
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
21.53%
High
Free cash flow margin (FCF)
29.89%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.86x
High
Margin stability
21.6 pts
Very uneven
Revenue to net income
Growth
5.1/10Revenue up 12.0% over 1 year, 14.2% a year over 5, EPS 8.3% a year over 5.
Revenue (trailing 12 months)
12.7Md USD
Revenue growth (1y)
11.99%
Strong
Revenue growth (3y)
38.02%
Solid
EPS growth (1y)
8.02%
Moderate
EPS CAGR (5y)
8.28%
Fair
EPS revisions (3 months)
-15.55%
Sharply revised down
Valuation
4.7/10P/E 30.3x, forward P/E 53.6x, EV/EBITDA 24.6x, PEG 3.66. The multiple sits in the 88th percentile of its own 5-year history.
P/E (TTM)
30.3x
Fair
Sector 29.6x|S&P 23.0x
Forward P/E
53.6x
Fair
EV / EBITDA
24.6x
Fair
Sector 23.2x|S&P 14.5x
PEG
3.66
Very expensive
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
442.07 USD
Overvalued
P/E vs its own 5-year history
among the 12% highest valuations
At its historical high
Market cap
131Md USD
Financial strength
10.0/10Cash covers 397.6% of the debt, net debt/EBITDA -0.9x.
Net debt / EBITDA
-0.9x
Net cash
Gearing (net debt / equity)
-29.07%
Net cash
Cash
7.9Md USD
Cash / market cap
6.01%
Tight
Cash / total debt
397.60%
Net cash
Interest coverage
359.2x
Very solid
Net debt
-5.9Md USD
Equity
20.2Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 522.38 USD
- MM20527.93
- MM50513.50
- MM200471.43
- RSI 1450.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.20%
200-day average slope, 3 months
+6.86%
50-day average slope, 1 month
+3.72%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.20 % per day
Volatility change
-30.03%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 9.73 (10) | 16.17 (15) | 13 247 (16) | 3 864 (3) | 2 535 (10) |
| 2027 | 18.45 (10) | 20.10 (15) | 14 547 (15) | 6 205 (4) | 4 833 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 3 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 4 | VRTX | 6.3 | 5.9 | 131Md USD | 30.3x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 35.3 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
